| Project/Area Number |
25870477
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Neurology
Applied pharmacology
|
|---|
| Research Institution | The University of Tokushima |
|---|
Principal Investigator |
MATSUI Naoko 徳島大学, 大学病院, 診療支援医師 (10547954)
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 重症筋無力症 / Finglimod / 胸腺 / recent thymic emigrant / fingolimod / Fingolimod |
|---|
| Outline of Final Research Achievements |
We aimed to examine the effect of fingolimod on recent thymic emigrant (RTE). Peripheral blood mononuclear cells were obtained from 4 healthy subjects and 10 patients with multiple sclerosis (MS). Blood sampling for the patients with MS was performed before and after the administration of fingolimod (in 1, 6, and 12 months). CD3+CD4+ T, naive T (CD45RA+, CD45RO-), and memory T cells (CD45RA-, CD45RO+) were identified by FACS. We also analyzed naive T’s expression of CD31, a surrogate marker of RTE. The frequency of memory T cells was relatively increased, but that of RTE was decreased in MS. Effect of fingolimod on RTE continued over one year. Fingolimod act as a potent antagonist at sphingosine 1-phosphate receptor type 1 (S1P1) on lymphocytic emigration from secondary lymphoid organs as well as thymus. In myasthenia gravis (MG), removal of thymus results in RTEs. We speculate that fingolimod have a possibility of the pharmacological effect similar to thymectomy.
|
